Medsmart Wellness Centers, a Subsidiary of Med Holdings Group Inc., Expands Telemedicine and Announces Strategic Partnerships
DENVER, CO AND MIAMI, FL / ACCESSWIRE / September 12, 2024 / Med Holdings Group Inc. (OTC PINK:YUKA), the parent...
Month: September 2024
Sema Slim: A New Safe and Effective Medical Weight Loss Solution Now Available Online
MIAMI, FL / ACCESSWIRE / September 12, 2024 / Sema Slim™, the premier online destination for effective telehealth services in...
Beacon Oral Specialists Announces Strategic Partnerships With Oral Surgery Partners and Vero Beach Surgical Arts
Newest Agreements Welcome Five Surgeons; Expand Footprint in Southern California, FloridaDALLAS, TX / ACCESSWIRE / September 12, 2024 / Beacon...
CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
Phase 2 data demonstrated positive immune responses to A and B strains, with acceptable safety and reactogenicity profile, meeting all...
Yunu Extends Free Cancer Center Use of Platform for All Children’s Oncology Group Clinical Trials
CARY, NC / ACCESSWIRE / September 12, 2024 / Yunu, a leading provider of clinical trial imaging workflow and data...
Interactive Strength Inc. (Nasdaq: TRNR) Secures Global Vendor Status with Industry Leader RSG Group for CLMBR
RSG Group owns Gold's Gym, McFIT, John Reed among other brandsThere are more than 900 locations in the group AUSTIN,...
University of California Transforms Life Science Research Procurement with Labviva
University of California selects AI purchasing platform to accelerate scientific and research procurement for 10 campusesOAKLAND, Calif., Sept. 12, 2024...
HeartSciences Closes Non-Dilutive Financing to Increase its Cash Runaway Ahead of Upcoming FDA Submission
Southlake, TX, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the...
PeopleOne Health and RosenCare Enhance Employee Healthcare with Innovative Model for Orange County Public Schools
Four new health centers to open across Orlando, boosting access to high quality and affordable healthcare in the regionORLANDO, Fla.,...
Scilex Holding Company Announces It Has Received the Drug Distributor Accreditation from the National Association of Boards of Pharmacy® (NABP®)
PALO ALTO, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating...
ReWalk Robotics Ltd. Finalizes Corporate Name Change to Lifeward Ltd.
Following approval by the shareholders and the Israel Companies Registrar, Lifeward has completed is rebranding initiative with a formal name...
Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301
$10 Million of additional Capital Recently Raised Strengthening Balance SheetKANSAS CITY, Kan., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:...
Kane Biotech Announces Exercise of Warrants
WINNIPEG, Manitoba, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces the...
Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for Ebola
GAITHERSBURG, Md., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it was awarded a contract...
Johnson & Johnson seeks first EU approval of nipocalimab to treat a broad population of patients living with antibody-positive generalised myasthenia gravis
Marks first EMA submission for nipocalimab, an investigational treatment that binds with high affinity and specificity to block FcRn and...
Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment
Innovative compounds designed to address critical unmet needs in PTSD treatment Vancouver, Canada, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Clearmind...
NKGen Biotech’s Positive Phase 1 Clinical Data in Moderate Alzheimer’s Disease Advances Troculeucel into Phase 2 with First Patient Dosed in Phase 1/2a Trial
Two of the first three patients in the Phase 1 cohort of the Phase 1/2a clinical trial, treated at the...
Noom Introduces Industry-First $149 Compounded GLP-1 with a Taper-Off Guarantee, Offering a Sustainable Approach to Long-Term Weight Loss
Starting price of $149 offers improved accessibility compared to market prices of brand-name medications which can be 8x higher.Noom stands...
VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor
VYN202 was generally well tolerated with no drug-related adverse eventsPharmacokinetic results demonstrated dose-dependent exposure of VYN202 in blood Pharmacodynamic activity observed...
Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr
WILMETTE, Ill., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing...